Manic Episode After a Chikungunya Virus Infection in a Bipolar Patient Previously Stabilized With Valproic Acid

Figueiredo, Tiago; Costa, Marcellus Dias da; Segenreich, Daniel

doi:10.1097/jcp.0000000000000887

Cited by 8 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, non-PD organoids had down regulation of IL-1 and IL-10 in response to CHIKV. This aligns with studies that have shown that reduced expression of IL-1 and IL-10 can exacerbate mental illness or psychotic episodes following infection with CHIKV [ 82 , 83 , 84 ].…”

Section: Discussionsupporting

confidence: 87%

Cerebral Organoids Derived from a Parkinson’s Patient Exhibit Unique Pathogenesis from Chikungunya Virus Infection When Compared to a Non-Parkinson’s Patient

Schultz

Jones

et al. 2021

Pathogens

View full text Add to dashboard Cite

(1) Background: Arboviruses of medical and veterinary significance have been identified on all seven continents, with every human and animal population at risk for exposure. Like arboviruses, chronic neurodegenerative diseases, like Alzheimer’s and Parkinson’s disease, are found wherever there are humans. Significant differences in baseline gene and protein expression have been determined between human-induced pluripotent stem cell lines derived from non-Parkinson’s disease individuals and from individuals with Parkinson’s disease. It was hypothesized that these inherent differences could impact cerebral organoid responses to viral infection. (2) Methods: In this study, cerebral organoids from a non-Parkinson’s and Parkinson’s patient were infected with Chikungunya virus and observed for two weeks. (3) Results: Parkinson’s organoids lost mass and exhibited a differential antiviral response different from non-Parkinson’s organoids. Neurotransmission data from both infected non-Parkinson’s and Parkinson’s organoids had dysregulation of IL-1, IL-10, and IL-6. These cytokines are associated with mood and could be contributing to persistent depression seen in patients following CHIKV infection. Both organoid types had increased expression of CXCL10, which is linked to demyelination. (4) Conclusions: The differential antiviral response of Parkinson’s organoids compared with non-Parkinson’s organoids highlights the need for more research in neurotropic infections in a neurologically compromised host.

show abstract

Section: Discussionsupporting

confidence: 87%

Cerebral Organoids Derived from a Parkinson’s Patient Exhibit Unique Pathogenesis from Chikungunya Virus Infection When Compared to a Non-Parkinson’s Patient

Schultz

Jones

et al. 2021

Pathogens

View full text Add to dashboard Cite

show abstract

“…A previous case reported that Chikungunya virus (CHIKV) infection might act as a trigger for manic episode in a bipolar patient, however, the underlying mechanisms remain poorly investigated ( Figueiredo et al, 2018 ). One explanation could be the direct effect of virus in CNS.…”

Section: Discussionmentioning

confidence: 99%

First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder

Wei

Jiang

et al. 2020

Journal of Affective Disorders

View full text Add to dashboard Cite

show abstract

“…Additionally, neuroinflammation secondary to viral infection is a plausible etiology for CNS cellular damage and neuropsychiatric pathogenesis. For example, in patients infected with arboviruses (e.g., Zika virus, Chikungunya virus) who presented with new cognitive impairment or precipitation of manic episodes, 32 severe inflammatory systemic response (pro‐inflammatory molecules in the CNS) and postinfectious, immune‐mediated phenomena (presence of brain‐reactive antibodies) appear to be the main factors implicated in the pathophysiology of viral‐related neuropsychiatric symptoms. Similarly, overproduction of pro‐inflammatory cytokines (cytokine storm) and exacerbated cytotoxicity has been described in COVID‐19 patients, 33 which have been associated with the onset of neurological and neuropsychiatric symptoms 34 .…”

Section: Discussionmentioning

confidence: 99%

Remitting neuropsychiatric symptoms in COVID‐19 patients: Viral cause or drug effect?

Forero‐Peña

Hernandez

Herrera

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

Numerous reports of neuropsychiatric symptoms highlighted the pathologic potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its relationship the onset and/or exacerbation of mental disease. However, coronavirus disease 2019 (COVID-19) treatments, themselves, must be considered as potential catalysts for new-onset neuropsychiatric symptoms in COVID-19 patients. To date, immediate and long-term neuropsychiatric complications following SARS-CoV-2 infection are currently unknown. Here we report on five patients with SARS-CoV-2 infection with possible associated neuropsychiatric involvement, following them clinically until resolution of their symptoms. We will also discuss the contributory roles of chloroquine and dexamethasone in these neuropsychiatric presentations.

show abstract

Manic Episode After a Chikungunya Virus Infection in a Bipolar Patient Previously Stabilized With Valproic Acid

Cited by 8 publications

References 16 publications

Cerebral Organoids Derived from a Parkinson’s Patient Exhibit Unique Pathogenesis from Chikungunya Virus Infection When Compared to a Non-Parkinson’s Patient

Cerebral Organoids Derived from a Parkinson’s Patient Exhibit Unique Pathogenesis from Chikungunya Virus Infection When Compared to a Non-Parkinson’s Patient

First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder

Remitting neuropsychiatric symptoms in COVID‐19 patients: Viral cause or drug effect?

Contact Info

Product

Resources

About